6019-39-2

Basic information

• Product Name: Benzamide, N-1H-indol-5-yl-
• Synonyms: OAC2;CS-2128;OAC2?, >98%;OAC-2;OAC 2;5-benzoylaminoindole;N-(1H-Indol-5-yl)benzaMide;Benzamide, N-1H-indol-5-yl-
• CAS NO: 6019-39-2
• Molecular Formula: C₁₅H₁₂N₂O
• Molecular Weight: 236.27
• Product Categories: Inhibitors;Aromatics, Heterocycles, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 6019-39-2.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 364.3±15.0 °C(Predicted)
• Appearance: /
• Density: 1.307±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 13.99±0.43(Predicted)
• CAS DataBase Reference: Benzamide, N-1H-indol-5-yl-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzamide, N-1H-indol-5-yl-(6019-39-2)
• EPA Substance Registry System: Benzamide, N-1H-indol-5-yl-(6019-39-2)

Safety Data

• Hazardous Substances Data: 6019-39-2(Hazardous Substances Data)

Usage

Description

Octamer-binding transcription factor 4 (Oct4) is a transcription factor which, with Sox2, Klf4, and c-Myc, is involved in the reprogramming of somatic cells to produce pluripotent stem cells. OAC2 is an Oct4-activating compound which activates expression through the Oct4 gene promoter. In cells expressing Oct4 with Sox2, Klf4, and c-Myc, OAC2 (1 μM) enhances reprogramming efficiency by increasing the rate of production of induced pluripotent stem cells (iPSCs) from embryonic fibroblasts. The iPSCs developed using OAC2 retain the capacity for pluripotent differentiation, whether evaluated in vitro or in vivo.

Uses

N-(1H-Indol-5-yl)benzamide is a octamer-binding transcription factor 4 activating compound that activated Oct4 and Nanog promoters, which are essential regulators of embryonic stem cell (ESC) pluripotency and key to the reprogramming process.

Upstream product

• 5192-03-0 5-amino-1H-indole 
• 65-85-0 benzoic acid 
• 61650-22-4 N-(pivaloyloxy)benzamide 
• 144104-59-6 1H-indole-5-boronic acid 
• 6146-52-7 5-nitroindole 
• 33632-27-8 1-(5-nitro-2,3-dihydroindol-1-yl)ethanone 
• 32692-19-6 5-nitro-2,3-dihydro-1H-indole 
• 98-88-4 benzoyl chloride 

Downstream Products

• 156499-24-0 3-(5-benzoylaminoindol-3-yl)-N-methylsuccinimide 
• 156499-25-1 5-benzylamino-3-(N-methylpyrrolidin-3-yl)indole 

Relevant articles and documents

Rhodium-catalyzed electrophilic amination of arylboronic acids with secondary hydroxylamines

A rhodium(III)-catalyzed electrophilic amination of arylboronic acids with secondary hydroxylamines has been developed. The rhodium catalysis is compatible with heteroarylboronic acids as well as acyl and alkoxycarbonyl protecting groups on the nitrogen of O-acylhydroxylamines, and the corresponding secondary anilines are obtained in good to excellent yields.

NOVEL RHO KINASE INHIBITORS AND METHODS OF USE

The subject invention concerns materials and methods for treating diseases and disorders associated with expression of Rho associated kinases (ROCKs). Examples of diseases and disorders contemplated within the scope of the invention include, but are not limited to, oncological disorders, cardiovascular diseases, CNS disorders, and inflammatory disorders. In one embodiment, a method of the invention comprises administering a therapeutically effective amount of one or more compounds of the present invention, or a composition comprising the compounds, to a person or animal in need of treatment. The subject invention also concerns compounds that inhibit ROCKs, and compositions that comprise the inhibitor compounds of the invention. Compounds contemplated within the scope of the invention include, but are not limited to, those compounds shown in Table (5).

PHARMACEUTICAL COMPOUNDS

The invention provides a compound for use in the prophylaxis or treatment of a disease state or condition mediated by a p38 MAP kinase such as rheumatoid arthritis and osteoarthritis; the compound being of the general formula (I): wherein U, T, V and W are each a nitrogen atom or a group CR4 provided that no more than three of U, T, V and W are nitrogen atoms; R0 is hydrogen, C1-4 hydrocarbyl, halogen or a group -A-R3; R1 is hydrogen, C1-4 hydrocarbyl or a group -A-R3; provided that only one of R0 and R1 is a group -A-R3; R2 is hydrogen, C1-4 hydrocarbyl or halogen; A is a carbon- or heteroatom-containing linker group having a linking chain length of one or two atoms; R3 is a monocyclic or bicyclic heteroaryl group containing from five to twelve ring members; each group R4 is independently selected from hydrogen, hydroxy, halogen, nitro, cyano, a monocyclic heterocyclic group having up to seven ring members, a group N(R5)2, a group C(O)N(R6)2, a group S02N(R6)2, a group Ra-Rb and a group Y; provided that no more than one group Y is present; Ra is a bond, O, S, SO, S02, NH or N-C1-4 hydrocarbyl; Rb is C1-8 hydrocarbyl optionally interrupted by O, S, SO, SO2, NH or N-C1- 4 hydrocarbyl and optionally substituted by one or more substitutents selected from hydroxy, amino, mono- or di-C1-4 hydrocarbylamino, C1 -4 hydrocarbyloxy, oxo, C1 -4 hydrocarbylthio and halogen; each group R5 is independently selected from hydrogen, C1-4 alkyl, C1-4 acyl and C 1-4 alkylsulphonyl; each group R6 is independently selected from hydrogen and C1-4 hydrocarbyl; Y is a group -N(R7)-C(O)-R8 or -N(R7)_SO2-R8; R7 is hydrogen, C1-4 hydrocarbyl or a group C(O)-R8 or S02-R8; R8 is selected from C1-l0 hydrocarbyl, CI-10hydrocarbylamino, CI-10 hydrocarbylthio, C1-l0 hydrocarbyloxy, and aryl, arylamino, arylthio and aryloxy groups, the aryl moieties of which are carbocyclic or heterocyclic and have from five to twelve ring members, each substituent group R8 being optionally substituted by one or more groups R4 other than Y; or R7 and R8 together with the nitrogen and carbon or sulphur atoms to which they are attached are linked to form a ring structure of 4 to 7 ring members; wherein R0 is other than a 2-(2,4-diamino-6-triazinyl)ethyl group when, in combination, U, T, V and W are all CH, and R1 and R2 are both hydrogen; and provided that when the group -A-R3 contains an acidic substitituent group selected from carboxylic, phosphonic and sulphonic acids and tetrazoles, or contains a -C(O)NSO2- group, or when -A- is -C(O)N- and the nitrogen atom of the group A is linked directly to a furan or thiophene ring, then either R1 is -A-R3 and both R0 and R2 are hydrogen, or R0 is-A-R3 and R1 is hydrogen.